Metoprolol succinate IP 47.5 mg equivalent to Metoprolol tartrate 50 mg in extended release dosage form and hydrochlorothiazide IP equivalent to 12.5 mg in immediate release dosage form are included in this fixed dose drug combination.


This medication is indicated for the treatment of moderate to severe hypertension, reducing the workload on the heart or other blood vessels, preventing strokes or heart attacks, and treating hypertensive emergencies.

Side effects

Mild to moderate side effects have been reported. In severe cases, side effects include dizziness, nausea, headache, fatigue, troubled breathing, lightheadedness, increased thirst, decreased urination, diarrhea, slow heart rate, muscle pain or cramps in the abdominal region, loss of appetite, unusual weakness or tiredness, mood changes, distended neck veins, and blurred vision.


This medication is to be prescribed cautiously in patients with severe diarrhea. Not to be taken before driving or in patients working with heavy machinery; avoid drinking alcohol after taking this medication.


This medication is contraindicated in patients with known previous histories of hypersensitivity to metoprolol, hydrochlorothiazide, or any of its other constituents. Severe bradycardia, sick sinus syndrome, second or third-degree heart block, or atrioventricular blockage.

Dosage and administration

In adults with hypertension, the usual dosage of immediate-release medication consists of hydrochlorothiazide up to 25–50 mg and metoprolol 100–200 mg orally to be administered orally once a day, as a single dose or in divided doses. Hydrochlorothiazide 12.5 mg and Metoprolol 25 mg are to be administered orally once a day, post meals, in extended-release medication. The maximum dose can be increased up to 25 mg of hydrochlorothiazide and 200 mg of metoprolol.


We have also established roots and begun this new venture in other countries as well, such as Iraq, Turkey, Belize, Singapore, the Philippines, Vietnam, Malta, and Nauru.

Available Forms